Vivasor, Inc.
10Patents
10Active
10Granted
53Portfolio score
Filing activity: Jan 21, 2020 → Jun 15, 2023
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US12084503B2 | Fully human antibodies that bind to vascular endothelial growth factor receptor 2 (VEGFR2) and methods of use thereof for treatment | Chemistry; Metallurgy | 2 | Active |
| US12201608B2 | Methods for treating Parkinson's disease by administering resiniferatoxin | Human Necessities | 0 | Active |
| US11987554B2 | Protease inhibitors as antivirals | Human Necessities | 0 | Active |
| US12138415B2 | Increased bioavailability of transdermally delivered agents | Human Necessities | 0 | Active |
| US11999792B2 | Antibody therapeutics that bind CD38 | Chemistry; Metallurgy | 0 | Active |
| US12064582B2 | Composite microneedle array including nanostructures thereon | Emerging Cross-Sectional Technologies | 0 | Active |
| US12029725B2 | Method for treating osteoarthritis pain by administering resiniferatoxin | Human Necessities | 0 | Active |
| US11987622B2 | Drug-conjugates with a targeting molecule and two different drugs | Chemistry; Metallurgy | 0 | Active |
| US12180294B2 | Dimeric antigen receptors | Chemistry; Metallurgy | 0 | Active |
| US12144886B2 | Perineural administration of resiniferatoxin for treatment of maladaptive pain | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.